Cancer cells can divert metabolites into anabolic pathways to support their rapid proliferation and to accumulate the cellular building blocks required for tumour growth. However, the specific bioenergetic profile of invasive and metastatic cancer cells is unknown. Here we report that migratory/invasive cancer cells specifically favour mitochondrial respiration and increased ATP production. Invasive cancer cells use the transcription coactivator peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PPARGC1A, also known as PGC-1α) to enhance oxidative phosphorylation, mitochondrial biogenesis and the oxygen consumption rate. Clinical analysis of human invasive breast cancers revealed a strong correlation between PGC-1α expression in invasive cancer cells and the formation of distant metastases. Silencing of PGC-1α in cancer cells suspended their invasive potential and attenuated metastasis without affecting proliferation, primary tumour growth or the epithelial-to-mesenchymal program. Inherent genetics of cancer cells can determine the transcriptome framework associated with invasion and metastasis, and mitochondrial biogenesis and respiration induced by PGC-1α are also essential for functional motility of cancer cells and metastasis.
It is generally well established that dividing cells, including cancer cells, meet their metabolic demands through the process of aerobic glycolysis 1, 2 . The energy generated through aerobic glycolysis is thought to be sufficient to offset the energy demands associated with rapid cancer cell division, while simultaneously allowing accumulation of biosynthetic precursors needed for anabolic reactions 1, 2 . Despite enhanced glycolysis, cancer cells also operate mitochondrial respiration to derive a significant fraction of their ATP (ref. 3) . In a growing tumour, adaptive metabolic reprogramming, precipitated in part by oncogenic transformation 4 , gives cancer cells a proliferative advantage 5, 6 . The autonomous metabolic reprogramming of rapidly proliferating cancer cells promotes selfsustaining signal transduction mechanisms to foster growth and survival 5 . However, the metabolic requirements of invasive and metastatic cancer cells that suspend their proliferative program to acquire a migratory phenotype are unknown. An improved understanding of the energetic demands of invading cancer cells may inform therapeutic strategies to impair metastasis, the primary reason for death in cancer patients. We set out to conduct experiments to study the specific energy requirements of invasive and metastatic cancer cells, with a hope of unraveling additional mechanisms of metastasis.
RESULTS
Circulating cancer cells exhibit enhanced mitochondria biogenesis and respiration GFP-labelled 4T1 mammary epithelial cancer cells were orthotopically implanted in the mammary fat pads of mice (Fig. 1a,b) . Primary tumours emerge following implantation of cancer cells into the mammary fat pads of female mice and lung metastases develop with 100% penetrance were assayed by gene expression microarrays. Gene expression profiling coupled with bioinformatic analyses revealed that the oxidative phosphorylation was the most differentially modulated canonical pathway in CCCs when compared with PCCs, with a significant increase in transcript levels associated with oxidative phosphorylation in CCCs (Fig. 1c,d ). The actin cytoskeleton signalling pathway was also differentially regulated in CCCs compared with PCCs ( Fig. 1d and Supplementary Fig. 1 ). We did not observe a significant deregulation in glycolysis/gluconeogenesis, pyruvate metabolism, the TCA cycle, the pentose phosphate pathway, amino sugar metabolism, fatty acid metabolism, fatty acid elongation in the mitochondria, phospholipids degradation, glycine/serine/threonine metabolism, arginine/proline metabolism, phenylalanine metabolism, and valine/leucine/isoleucine metabolism in CCCs compared to PCCs ( Fig. 1d and Supplementary Fig. 1 ).
A R T I C L E S
Quantitative PCR analyses showed specific upregulation of genes associated with mitochondrial biogenesis (PGC-1α (coding for PGC-1α), PGC-1β (PGC-1β), Nrf1 and Esrra (ERRα)) and oxidative phosphorylation (Cox5b, Cox4i1 (Cox4i), Atp5a1 (ATPsynth) and Cycs (CytC)) in CCCs compared with PCCs (Fig. 2a ). MCCs and PCCs showed similar gene expression levels associated with mitochondria biogenesis and oxidative phosphorylation (Supplementary Fig. 2A ), suggestive of a reversible expression of these genes when CCCs are retained in their preferred site of metastasis. The expression levels of some MCC genes were only partially restored to values obtained in PCCs, and this may be due to a collective mixture of MCCs at different stages of metastasis (arrest, extravasation, migration, proliferation). The reversible shift in patterns of metabolic gene expression paralleled that of genes frequently associated with an epithelial-to-mesenchymal transition (EMT) program ( (e-h) Mitochondrial DNA (mtDNA) content (n = 5 DNA samples from 5 mice, one-way ANOVA; e), intracellular ATP levels (n = 3 lysates from 3 mice, one-way ANOVA; f), OCR (g), and mitochondrial OCR (delta OCR pre and post rotenone treatment; h) in PCCs, CCCs and MCCs from the 4T1 orthotopic tumour model (n = 3 wells of cells from 3 mice, one-way ANOVA). Data are presented as mean ± s.e.m. NS, not significant. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001.
and Supplementary Fig. 2A ). Activation of an EMT program is a characteristic feature of invading epithelial cancer cells 8, 9 . Mesenchymal genes (Twist1 (Twist), Snai1 (Snail) and Acta2 (αSMA)) were significantly upregulated in CCCs, whereas epithelial genes (Krt8 (CK8) and Cdh1 (E-cadherin)) were downregulated in CCCs when compared with PCCs and MCCs ( Fig. 2a and Supplementary  Fig. 2A ). Genes associated with thermogenesis, uncoupled respiration (Ucp1) and lipid biosynthesis (Acc, Elovl6 and Fasn) were unchanged ( Fig. 2a) in CCCs compared to PCCs. Collectively, these results suggest that CCCs assume a characteristic EMT phenotype and transition to a bioenergetic program that uses mitochondrial biogenesis and oxidative phosphorylation.
PGC-1α is enriched in CCCs
The enhanced mitochondrial oxidative phosphorylation in CCCs compared with PCCs and MCCs was associated with a marked upregulation of PGC-1α, which codes for PGC-1α, an inducer of mitochondrial biogenesis (Fig. 2a,b) . PGC-1α functions as a master integrator of cellular signals that regulate mitochondrial biogenesis, oxidative phosphorylation, adaptive thermogenesis and fatty acid biosynthesis/degradation 10, 11 . PGC-1α promotes ATP production and energy homeostasis during bioenergetic crises, which renders cells resistant to necrosis and apoptosis 12 . PGC-1α has been implicated in tumorigenesis 13, 14 , yet its function in metastasis remains unknown. PGC-1α expression in CCCs was highest among all other genes known to promote mitochondria biogenesis, including Esrra, Nrf1 and PGC-1β (Fig. 2a) . Immunostaining for PGC-1α in PCCs and CCCs shows an increase in the percentage of PGC-1α
+ CCCs compared with PCCs ( Fig. 2c) . PGC-1α expression was not detected in peripheral blood cells that were isolated from non-tumour-bearing mice (Fig. 2d) . We measured PGC-1α expression levels in CCCs isolated from the MMTV-PyMT spontaneous mouse breast cancer model (these mice spontaneously develop primary mammary tumours that metastasize primarily to the lung 15, 16 ), as well as in CCCs from mice harbouring a variety of orthotopically implanted tumours, including B16F10 mouse melanoma, MDA-MB-231 (triple-negative human breast cancer cells), MDA-MB-435 human melanoma 17 and 786-O human renal cell carcinoma. In all of the models studied, PGC-1α expression was markedly upregulated in CCCs compared with PCCs ( Fig. 2d and Supplementary Fig. 2B ,C,E).
To determine whether increased expression of genes associated with mitochondria biogenesis and oxidative phosphorylation in CCCs correlated with increased mitochondria number and mitochondrial respiration, we first measured the oxygen consumption rate (OCR), ATP production and mitochondria DNA content in purified CCCs (Fig. 2e-h ). When compared with PCCs, CCCs exhibited an increased mitochondrial DNA content (Fig. 2e) , an elevated intracellular ATP levels (Fig. 2f) , a higher basal respiration rate (Fig. 2g) and an enhanced mitochondrial OCR (Fig. 2h) . The mitochondrial DNA content of CCCs from mice with B16F10 and MDA-MB-231 tumours was also increased ( Supplementary Fig. 2D,F) . These results suggested that the enhanced oxidative phosphorylation was associated with an increase in the number of mitochondria per cell and that enhanced PGC-1α expression and mitochondrial biogenesis are features of CCCs.
PGC-1α expression facilitates mitochondria biogenesis and invasion of cancer cells PGC-1α was silenced (gene expression knockdown, PGC-1α shRNA) or overexpressed (adenoviral-induced overexpression, Ad. PGC-1α) in 4T1, B16F10 and MDA-MB-231 cells (Fig. 3a,b and Supplementary Figs 4A,B and 5A,B). Quantitative PCR analyses revealed significant downregulation of genes associated with mitochondrial biogenesis (PGC-1α, Nrf1 and Esrra) and oxidative phosphorylation (Cycs and Cox5b) in PGC-1α shRNA 4T1 cells compared with Scrbl shRNA 4T1 control cells. Genes associated with lipid biosynthesis (Acc, Elovl6 and Fasn) and an EMT program (Krt8, Cdh1, Twist1, Snai1 and Acta2) were unchanged (Fig. 3a) . Induction of PGC-1α expression reversed the suppression of genes associated with mitochondrial biogenesis and oxidative phosphorylation in PGC-1α shRNA 4T1 cells, whereas genes associated with lipid biosynthesis remained unchanged (Fig. 3a) . A significant reduction in the PGC-1α transcript and protein levels in 4T1, B16F10 and MDA-MB-231 cells resulted in suppressed mitochondrial biogenesis, as assessed by reduced mitochondrial DNA (Fig. 3c and Supplementary Figs 4C and 5C) and a reduced amount of mitochondrial protein per cell ( Fig. 3d and Supplementary Figs 4D and 5D ). PGC-1α-depleted cells exhibited decreased cellular ATP levels ( Fig. 3e and Supplementary  Figs 4E and 5E ). Transmission electron microscopy analyses reveal reduced numbers of mitochondria and swollen mitochondria with disorganized cristae, suggesting impaired mitochondria respiration ( Fig. 3f and Supplementary Fig. 3A-D) . We verified this by measuring the OCR in a series of mitochondrial stress tests performed on cultured cells. These experiments indicated that mitochondrial respiration capacity was diminished when PGC-1α was suppressed (Fig. 4a-c and Supplementary Figs 4F and 5F ). Specifically, the basal respiration rate was decreased in PGC-1α shRNA cells compared with Scrbl shRNA control cells ('1' in Fig. 4a ). We noted an elevated nonmitochondrial OCR in Scrbl shRNA cells compared with PGC-1α shRNA cells ('2' in Fig. 4a ) following inhibition of electron transport chain (ETC) complex I+II (rotenone + atpenin A5 treatments). Targeted mass spectrometry and metabolomics analyses 18 of PGC-1α shRNA 4T1 cells compared with Scrbl shRNA 4T1 cells revealed lower levels of some of the metabolite levels associated with glycolysis, the TCA cycle, amino sugar metabolism, pyruvate metabolism, phospholipid metabolism, pyrimidine and purine metabolism, and some of these associated metabolites showed elevated levels ( Supplementary  Fig. 6A ). Metabolomics analyses of PGC-1α shRNA 4T1 cells cultured using 13 C-labelled glucose also showed insignificant differences in the accumulation rate of glycolytic/gluconeogenic metabolites when compared with Scrbl shRNA control cells ( Supplementary Fig. 7A ). OCR measurements also revealed a decreased capacity for ATPcoupled OCR in PGC-1α shRNA cells compared with Scrbl shRNA control cells (B < B in Fig. 4b ) and an enhanced proton leak (C > C in Fig. 4b ). PGC-1α shRNA cells respire at their maximal capacity (D < A in PGC-1α shRNA cells versus D > A in Scrbl shRNA cells in Fig. 4b ), possibly to compensate for the loss in ATP-coupled respiration subsequent to the loss of mitochondria, lowering the basal respiration rate. Mitochondrial OCR was decreased in PGC-1α shRNA cells compared with Scrbl shRNA cells, which also occurred when either complex I or complex I+II of the ETC was inhibited (Fig. 4c) . Compensation through complex II activity is not observed when mitochondrial respiration is compromised by suppression of PGC-1α in live cells; however, OCR measurements of permeabilized cells suggest a possible differential regulation of complex-II-linked OCR activity (increased OCR following succinate injection) in PGC-1α shRNA cells compared with Scrbl shRNA cells (Fig. 4d) . These results indicate that PGC-1α modulates mitochondrial biogenesis in cancer cells without significantly affecting Relative PGC-1 expression glycolysis. These results also suggest that PGC-1α suppression impacts the oxidative phosphorylation capacity of cancer cells by both suppressing mitochondrial biogenesis and directly impacting ATPcoupled respiration and the efficacy of the ETC within the remaining mitochondrial pool. The transition from PCCs to CCCs seems to be associated with enhanced reliance on mitochondrial respiration, which is probably mediated, in part, by PGC-1α. PGC-1β, Esrra and Nrf1 were upregulated in CCCs ( Fig. 2a ) and downregulated when PGC-1α was suppressed ( Fig. 3a) , highlighting an upstream action of PGC-1α in this setting 19 .
PGC-1α expression determines the invasive capacity and metastasis potential of cancer cells Next, we investigated whether PGC-1α-mediated induction of mitochondria biogenesis and respiration was associated with the invasive capacity of CCCs. We measured invasion, migration and cell division of 4T1, B16F10 and MDA-MB-231 cells with stable suppression, rescued expression or overexpression of PGC-1α, or with rotenone treatment. Suppression of PGC-1α revealed specific downregulation of mitochondrial respiration, but overexpression of PGC-1α in cancer cells resulted in a mixed metabolic response, probably resulting from the hyper induction of many metabolic processes due to supraphysiological levels of PGC-1α in cultured cells 12 ( Fig. 3a) . Nevertheless, overexpression of PGC-1α in PGC-1α shRNA cancer cells partially reversed the gene expression pattern associated with suppression of mitochondrial biogenesis and respiration (Fig. 3a) . PGC-1α knockdown and rotenone treatment significantly reduced invasion of cancer cells, and overexpression of PGC-1α enhanced invasion and restored invasive properties to PGC-1α shRNA cells (Fig. 5a,b and Supplementary Figs 3E, 4G,H and 5G,H). Migration was also dependent on PGC-1α expression levels (Fig. 5c,d and Supplementary Figs 3E, 4I,J and 5I,J), whereas alterations in PGC-1α expression had no effect on cell division (Fig. 5e) . Loss of PGC-1α expression reduced the ability of cancer cells to tighten type I collagen in contraction assays, suggestive of compromised actin cytoskeleton remodelling and associated ATP-fuelled molecular motors ( Fig. 5f and Supplementary
Figs 4K and 5K). Overexpression of PGC-1α alone did not enhance collagen I contraction, but rescued PGC-1α shRNA reduced type I collagen contractility ( Fig. 5f and Supplementary Figs 4K and 5K). Taken together, these results indicate that loss of PGC-1α expression diminishes invasive and migratory properties of cancer cells and these features are restored with the rescue of PGC-1α gene expression in PGC-1α shRNA cancer cells.
PGC-1α promotes cancer cell metastasis
Suppression of PGC-1α expression had no effect on the growth of primary 4T1 tumours (Fig. 6a,b) . PGC-1α shRNA MDA-MB-231 tumours showed similar tumour growth kinetics and weight when compared to control Scrbl shRNA MDA-MB-231 tumours ( Supplementary Fig. 8A,B) . Similarly, PGC-1α gene expression knockdown did not impact the growth of primary B16F10 melanomas * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001. (i) Number of lung surface nodules (Scrbl shRNA 4T1, n = 5 mice; PGC-1α shRNA 4T1, n = 6 mice, unpaired two-tailed Student's t-test). Data are presented as mean ± s.e.m. NS, not significant. * P < 0.05, * * * P < 0.001.
( Supplementary Fig. 8I,J) . The number of CCCs was significantly reduced in mice with PGC-1α shRNA 4T1 tumours compared with mice with control Scrbl shRNA 4T1, as assessed by the reduced number of GFP + cancer cells in the blood by FACS analysis and also by the decreased number of blood-derived cancer cell colonies (colony formation assay; Fig. 6c,d) . The decreased dissemination of cancer cells was associated with a significant reduction in the computed percentage of metastatic lung area and the number of surface lung nodules of mice with PGC-1α shRNA 4T1 tumours compared with mice with control Scrbl shRNA 4T1 tumours (Fig. 6e,f) . These findings were reproduced using a second knockdown clone of PGC-1α in 4T1 cells ( Supplementary Fig. 7B-E) . CCC numbers ( Supplementary  Fig. 8C,D) and metastasis ( Supplementary Fig. 8E,F) were also significantly reduced in mice bearing PGC-1α shRNA MDA-MB-231 tumours in contrast with mice bearing Scrbl shRNA MD-MB-231 tumours. Decreased cancer cell dissemination and reduced metastatic disease were also observed when PGC-1α expression was suppressed in B16F10 melanoma cells ( Supplementary Fig. 8K-N) . These results indicate that suppression of PGC-1α reduces cancer cell metastasis.
Our studies pointed to the possibility that PGC-1α expression is essential for intravasation of the cancer cells into the circulation. Similar anchorage-independent survival (anoikis) rates in cells with suppressed PGC-1α was observed compared with control lines (Fig. 6g) . We next investigated whether extravasation of cancer cells is similarly impaired when PGC-1α is suppressed. We monitored lung colonization and lung metastatic nodule formation in mice following intravenous injection of PGC-1α shRNA and control Scrbl shRNA cells. Metastatic lung colonization and nodule formation were significantly impaired when PGC-1α expression was suppressed (Fig. 6h,i and Supplementary Fig. 8G ,H,O,P). Taken together, our results support an important role for PGC-1α-mediated mitochondrial biogenesis and oxidative phosphorylation in facilitating migration, invasion and intravasation/extravasation of cancer cells.
A R T I C L E S
Mitochondrial respiration fuels cancer cell motility To evaluate PGC-1α expression in invading cancer cells in vivo, we FACS-purified PCCs on the basis of GFP expression and αSMA labelling. Cancer cells exhibiting an EMT program (GFP + /αSMA + ) express significantly higher levels of PGC-1α when compared with cancer cells without an EMT program (GFP + /αSMA − ) (Fig. 7a ). Hypoxia is a potent inducer of the invasive properties of cancer cells, and thus we evaluated PGC-1α expression in 4T1, B16F10 and MDA-MB-231 cells following re-oxygenation from hypoxia. PGC-1α expression was significantly increased following reoxygenation (Fig. 7b) . Cells in hypoxia as well as after re-oxygenation showed elevated PGC-1α and Twist expression (Fig. 7c) . However, when PGC-1α was suppressed, hypoxia had no effect on PGC-1α expression, but did upregulate Twist1 expression, suggesting that Twist1 expression associated with hypoxia-induced EMT was independent of PGC-1α upregulation (Fig. 7c) . Similarly, in cells with knockdown of Twist1 expression, PGC-1α expression was elevated under hypoxic conditions, whereas Twist1 was not upregulated (Fig. 7c) . Furthermore, double immunolabelling for CK8 (epithelial marker, Krt8) and αSMA (mesenchymal marker, Acta2) revealed a similar number of double-positive cancer cells in PGC-1α shRNA and control Scrbl shRNA primary tumours, suggesting an equal frequency of cancer cells acquiring an EMT program (Fig. 7d) . Quantitative PCR analyses for mesenchymal and epithelial genes showed comparable levels of EMT-program-related genes in both PGC-1α shRNA and control Scrbl shRNA primary tumours (Fig. 7e) . Immunolabelling for Twist1 and PGC-1α in CCCs indicated that most of the CCCs were PGC-1α + , and nearly all PGC-1α + CCCs were Twist + (Fig. 7f) . Taken together these results suggest that acquisition of an EMT and invasive phenotype is associated with Twist1 expression, and that PGC-1α upregulation in invasive cells is independent of Twist1 upregulation. The invasive feature of migrating cancer cells, which may be precipitated by hypoxia, was associated with elevated PGC-1α expression; however, suppression of PGC-1α did not impact the expression of EMT-related genes (Fig. 3a) . Collectively, these findings suggest that induction of PGC-1α expression is not mutually exclusive to the acquisition of mesenchymal features (EMT), and modulating mitochondrial respiration in cancer cells through hypoxia-driven induction of PGC-1α expression does not limit the induction of EMT-associated genes, but functionally impairs cell motility and invasive properties. Table 1 ). These data suggest a possible role for PGC-1α in mediating cancer cell dissemination to the bone in patients with IDCs.
We next probed tissue microarrays for the expression of PGC-1α in breast tumours from 161 patients with IDCs ( Fig. 8b and Supplementary Table 2 ). There was a significant correlation between high PGC-1α expression at the invasive tumour front and distant metastasis and, moreover, poor overall and cancer-specific survival (Fig. 8c,d) . We also detected PGC-1α expression in CCCs ('CTCs') collected from patients with metastatic IDCs, and PGC-1α + CTCs were negative for the leukocyte marker CD45 (Fig. 8e and Supplementary Table 3 ). In addition, CTCs were detected in 11 out of 13 patients with IDCs who had confirmed lung metastases and more than 80% of the CTCs were PGC-1α + (Fig. 8f and Supplementary Table 4 ). These results illustrate a positive correlation between PGC-1α expression and the formation of distant metastases in patients with invasive breast cancer.
DISCUSSION
New therapeutic strategies are beginning to focus on the unique patterns of metabolism observed in cancer cells. Therefore, determining the metabolic requirements of invasive cancer cells could be of therapeutic value. We show that the PGC-1α-mediated mitochondrial biogenesis and respiration in cancer cells is functionally relevant for metastatic dissemination. Invading cancer cells rely on PGC-1α to stimulate mitochondrial biogenesis and oxidative phosphorylation during their transit to target organs of metastasis. Indeed, PGC-1α suppression significantly impaired mitochondrial biogenesis and oxidative phosphorylation and, moreover, decreased the frequency of metastasis. The enhanced mitochondrial respiration/oxidative phosphorylation did not impact glycolytic and anabolic rates in the CCCs, and did not affect cancer cell proliferation or primary tumour growth kinetics. Although more studies are required to specifically connect PGC-1α-induced oxidative phosphorylation and metastasis, these results demonstrate that invasive and migratory properties of cancer cells are dependent on mitochondrial respiration and identify PGC-1α as a potential target for therapeutic intervention.
Mitochondrial proficiency and detoxification of reactive oxygen species (ROS) are critical for cancer cell viability 21, 22 . Although diminished oxygen levels feed back to reduce mitochondrial biogenesis to avoid metabolic crisis in normal cells 3, 4 , zonal hypoxia and focal nutrient bioavailability in different areas of a growing tumour can differentially impact the energetic needs of cancer cells. ROS accumulation in hypoxic cancer cells induces expression of PGC-1α/β to promote detoxification through direct induction of superoxide dismutase 2 (SOD2), catalase and glutathione peroxidase [23] [24] [25] . Focal hypoxia may induce an EMT program 16, 26 , and our results indicate that although cancer cells acquire a mesenchymal phenotype (EMT) independently of PGC-1α-induced pathways, both pathways coexist and are associated with cancer cell migration, invasion and metastasis 27 . We propose that a functional EMT program in cancer cells, with acquisition of enhanced migratory and invasive properties, is synergistically coupled with mitochondrial biogenesis and respiration. Altering mitochondrial function could also impact other fundamental cellular processes, in part through retrograde mitochondria-nucleus signalling, and contribute to changes in the nuclear transcriptome associated with survival and acquisition of cancer stem cell properties 28 . In addition, dynamic changes in the A R T I C L E S Table 2 , log-rank test). (d) Correlative analysis of the number of IDC patients with and without distant metastases categorized on the basis of the indicated PGC-1α expression threshold (Supplementary Table 2 , Fisher's exact test). Kaplan-Meier curves were drawn and differences between the curves were calculated by the log-rank test. (e) A circulating cancer cell ('CTC', right arrowhead) stains for the epithelial marker CK8, whereas leukocytes ('L', left arrowhead) are negative for CK8 (upper left panel). Leukocytes are negative for PGC-1α (upper right panel). Inset shows negative control (NC) staining of a CTC (secondary antibody alone). PGC-1α (patient 1 and 2) or CD45 and PGC-1α (patient 3 and 4) immunostaining of CTCs (lower panels, Supplementary Table 3 Table 4) . energy processing of cancer cells in disease progression probably impact the surrounding tumour stroma, which in turn may impact the migratory phenotype of cells.
We speculate that cells in the hypoxic areas of the tumour trigger acquisition of migratory features through EMT and PGC-1α-mediated mitochondrial respiration. It is conceivable that invading cancer cells enhance their mitochondrial content and upregulate oxidative phosphorylation as they approach more oxygenated areas of the tumour, which ensures the increased production of ATP required for trafficking to distal tissues. Mitochondrial proficiency and ROS detoxification are critical for cancer cell viability 21, 22 , and ATP generation (a feature of non-dividing migratory cells 3, 29 ) and antioxidant production ensure cancer cell survival when detaching from their basement membrane 30 . The high ATP production found in CCCs may be used to promote their retention in target organs. A recent study showed that ATP secreted from platelets stimulates endothelial cell retraction that promotes transendothelial migration of cancer cells 31 . Our clinical analysis of human invasive breast cancers revealed a significant correlation between PGC-1α expression in invasive cancer cells and formation of distant metastases. Of note, expression of ERRα (PGC-1α-coupled transcription factor) in IDC patients also correlates with poor prognosis 32 . Furthermore, PGC-1α expression was detected in a high percentage of CTCs of metastatic breast cancer patients. Our studies provide insight into uncovered dynamic shifts in the metabolic program of cancer cells to facilitate diverse steps associated with cancer progression and metastasis.
METHODS
Methods and any associated references are available in the online version of the paper. 17 ) and intravenous injections of cancer cells were performed as previously described 16, 33 . MMTV-PyMT mice were previously described 15 and emergence of primary and secondary tumours in these mice and the experimental endpoint at which PCCs, MCCs and CCCs were assayed were previously described 16 . Adult (at least 8 weeks of age) BALB/c female mice were used for 4T1 injections, adult C57BL/6 male or female mice were used for B16F0 injections, and adult female and male Nu/Nu mice were used for MDA-MB-231, 786-0 and MDA-MB-235 injections. n = 5-7 mice were used per experimental group. The metastatic surface area was computed as previously described 16 . No statistical method was used to predetermine sample size and the experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. The blood volume taken to collect CCCs was 200 µl. Blood was incubated with ACK lysis buffer . For stable transfection of PGC-1α, pre-designed shRNAs from Origene were used and puromycin-resistant clones were subsequently propagated. For overexpression of PGC-1α, recombinant adenovirus expressing PGC-1α or empty pcDNA control vector was provided by B. Spiegelman (Dana-Farber Cancer Institute, Boston, Massachusetts). For the proliferation rate, cells growing exponentially were counted twice at 12 h intervals and the respective proliferation rate was calculated. Hypoxia experiments were performed as previously described, and re-oxygenation included a 24 h incubation in normoxia (21% oxygen) following a 48 h exposure to hypoxia (1-2% oxygen).
Gene expression array and real-time PCR validation. RNA was extracted from PCCs, MCCs and CCCs using RNeasy Plus Mini Kit (Qiagen) and submitted to the Molecular Genetics Core Facility at the Children's Hospital. Microarray analysis was performed using Mouse Ref8 Gene Expression BeadChip (Illumina platform) and Metacore (GeneGo) and Knowledge Based Pathway (IPA; rank invariant normalization with subtracted background). Gene expression validation by real-time PCR was performed as previously described 16 using the primers listed in Supplementary Table 5 . Heat maps were drawn using R software. For PGC-1α expression in the laser-microdissected cancer cells from human invasive ductal carcinoma (IDC) tumour specimens, the SuperScript III One-Step RT PCR System from Invitrogen was used.
Relative mitochondrial DNA content measurements. Mitochondrial DNA (mtDNA) was measured by PCR analysis of total DNA extracted from mouse and human CCCs by assessing the relative levels of cytochrome oxidase 1 (mouse mtCO1: 5 -TTGGTCCCCTCCTCCAGC-3 and 5 -CCAGTGCTAGCCG CAGGCA-3 ) versus β-actin (Supplementary Table 5 ) and Arp/36b4 (5 -GGAGCC AGCGAGGCCACACTGCTG-3 and 5 -CTGGCCACGTTGCGGACACCCTCC-3 ) and human mtCO1 (5 -TGGAGCCTCCGTAGACCTAA-3 and 5 -TGCGAA GCCTGGTAGGATAA-3 ) versus β-globin (Supplementary Table 5 ). For mitochondria protein content, mitochondria were isolated as previously described 36 , with the following modifications: cells plated in 10 cm 2 tissue culture dishes were counted and pelleted at 450g for 5 min at room temperature. The cell pellet was re-suspended in 2 ml of mitochondria isolation medium (MIM) with BSA (MIM: 300 mM sucrose, 10 mM Na-HEPES, 0.2 mM EDTA, pH 7.2; 1 mg ml −1 BSA) and dounced homogenized. Lysates were spun at 450g for 10 min at 4 • C. The supernatant was then transferred to new tubes and spun at 15, 800g for 15 min at 4 • C. The mitochondria pellet was then washed once with 1 ml MIM+BSA and 1 ml MIM. The final pellet was re-suspended in 20 µl MIM. A 1:100 dilution of 20 µl MIM resuspension was used with the microBCA assay kit (PierceNet) following the manufacturer's directions. Protein content was normalized to cell count.
Measurement of oxygen consumption rate. The oxygen consumption rates (OCRs) were measured using the Seahorse XF24 and XF96 instruments (Seahorse Bioscience) under standard conditions and after the addition of 0.1 µM oligomycin, 0.05 µM FCCP, 1 µM rotenone and 10 µM atpenin A5. Real-time measurements (triplicates) of the OCR in picomoles per minute in tissue culture medium above cells plated in a microplate were plotted over time before the addition of rotenone to the culture media (basal OCR), and after addition of rotenone to specifically measure mitochondrial respiration. The difference in OCR before and after rotenone addition to the culture media reflects the oxygen consumption by mitochondria (mitochondrial OCR). The OCR measurements were adjusted to cell numbers plated. To this end, the cells were stained with crystal violet (0.1% weight per volume of water) following paraformaldehyde (PFA) permeabilization (4% PFA) and spectrophotometric measurements of 10% acetic-acid-solubilized cells were performed with a standard plate reader (Molecular Devices). For OCR measurements of permeabilized cells, the Seahorse plasma membrane pemeabilizer kit was used, allowing cells to permeabilize for 30 min, with media supplemented with 10 mM malate and 10 mM glutamate, and with sequential injection of 4 mM ADP, 2 µM rotenone, 10 mM succinate and 2.5 µM antimycin A.
ATP measurements. ATP measurements were obtained using the ATP Determination kit (Life Technologies). For the latter, cells were homogenized in lysis buffer (1% Triton X-100, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1% NaDOC) supplemented with protease cocktail inhibitor, Complete (Roche) and phenylmethylsulphonyl fluoride (Sigma-Aldrich). Protein was quantified by using the BCA Protein Assay (Thermo Scientific), which was used for normalization. Measurements were obtained using the fluorescence plate reader FLUOstar Omega (BMG Labtech). The samples were normalized to the protein concentration of the corresponding Scrbl shRNA cell line.
Transmission electron microscopy. Transmission electron microscopy imaging was performed at the High Resolution Electron Microscopy Facility at UTMDACC. Samples fixed with a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3, were washed in 0.1 M cacodylate buffer and treated with 0.1% Millipore-filtered buffered tannic acid, postfixed with 1% buffered osmium tetroxide for 30 min, and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were washed several times in water, then dehydrated in increasing concentrations of ethanol, infiltrated, and embedded in LX-112 medium. The samples were polymerized in a 60 • C oven for about 2 days. Ultrathin sections were cut in a Leica Ultracut microtome (Leica), stained with uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 1010 transmission electron microscope (JEOL) at an accelerating voltage of 80 kV. Digital images were obtained using the AMT Imaging System (Advanced Microscopy Techniques). For quantification, we examined 3-9 cells magnified at ×5,000 per group and counted the number of mitochondria per cell visualized in the sectioned image.
Targeted mass spectrometry analysis. For cultured cells as well as FACS-purified cells, 4 ml or 400 ml of 80% LC-MS-grade methanol was added to each 10 cm 2 dish or FACS sample respectively and incubated at −80 • C for 15 min. Cells were scraped off the dish using a sterile cell scraper and collected from the plate to be centrifuged at 18, 470g for 5 min in a cold room to pellet cell debris and proteins. Supernatants were saved. Pellets were resuspended in 500 µl 80% methanol by vortexing and subsequently centrifuged as before. Supernatants were centrifuged one final time at 18, 470g for 10 min at 4 • C. Metabolite extractions were dried to a pellet by SpeedVac with no heat. Samples were re-suspended using 20 µl LC-MS-grade water and 10 µl was injected and analysed using a 5500 QTRAP hybrid triple quadrupole mass spectrometer (AB/Sciex) coupled to a Prominence UFLC HPLC system (Shimadzu) through selected reaction monitoring (SRM). Two hundred and fifty-four endogenous water-soluble metabolites were targeted for steady-state analyses of samples. Some metabolites were targeted in both the positive and negative ion mode through positive/negative polarity switching for a total of 289 SRM transitions. The ESI voltage was +4900 V in the positive ion mode and −4500 V in the negative ion mode. The dwell time was 3 ms per SRM transition and the total cycle time was ∼1.56 s. Approximately 10-12 data points were acquired per detected metabolite. Samples were delivered to the MS through normal-phase chromatography using a 4.6 mm i.d × 10 cm Amide XBridge HILIC column (Waters) at 350 µl min −1 . Gradients were run starting from 85% buffer B (HPLC grade acetonitrile) to 35% B from 0-3.5 min; 35% B to 2% B from 3.5-11.5 min; 2% B was held from 11.5-16.5 min; 2% B to 85% B from 16.5-17.5 min; 85% B was held for 7 min to re-equilibrate the column. Buffer A was comprised of 20 mM ammonium hydroxide/20 mM ammonium acetate (pH 9.0) in 95:5 water/acetonitrile. Peak areas from the total ion current for each metabolite SRM transition were integrated using MultiQuant v2.0 software (AB/Sciex). Metabolomics data analysis was done in part using Metaboanalyst software (www.metaboanalyst.ca). For glucose isotopic tracer experiments, cells were placed in glucose-free media supplemented with 10% dialysed serum and with uniformly labelled [U- 13 C 6 ] glucose (Cambridge Isotope Laboratories) for 12 h before extraction for LC-MS/MS analyses. A set of SRM transitions was used to target the heavy form of each metabolite.
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Invasion and migration assays. For invasion assays, the polycarbonate membranes (8 µm pore) were coated on both sides with Matrigel and cells on the basal side of the membrane (post migration) were fixed in 100% ethanol and stained with haematoxylin before microscopic evaluation. For the scratch/migration assay, the cell-free area was measured 24 h after scratching the dish, and 0.1 µM rotenone was used.
Anoikis assay. Cells (5 × 10 6 ) were serum-starved in 0.5% FBS for 24 h. The cells were then counted and resuspended in 13 ml serum-free DMEM in a 15 ml Falcon tube and allowed to rock at 37 • C for 24 h. The cells were then pelleted and counted using a haemocytometer. Triplicate measurements of two cell counts were used to determine the percentage of cell viability.
Type I collagen contractibility assay. Cells were seeded at a density of 5 × 10 4 cells per well of 24-well plates on 3 mg ml −1 type I collagen gel. Stressed matrix was allowed to contract for 48 h and was then released. Collagen gel size change (average gel area) was measured with a ruler 24 h following release of stressed matrix.
FACS.
Tumours were resected, minced, and digested in 400 U ml −1 type II collagenase at 37 • C while shaking. Single-cell suspensions following filtering through 75 µm mesh were fixed in BD Cytofix/Cytoperm (BD Biosciences) and stained in 2% FBS containing PBS with DMEM with anti-mouse αSMA primary antibody and TRITC-conjugated secondary antibody. All FACS analyses were performed at the Joslin Diabetes Center Flow Cytometry Core. FACS-purified cells were spun down at 2, 000g for 10 min at 25 • C and the cell pellet was processed for quantitative PCR analysis using the Cells-to-cDNA kit (Ambion) according to the manufacturer's directions. CCCs and PCCs were also FACS-purified and cytospin (onto glass slides at 130g for 5 min) stained following a 10 min acetone fixation step at 4 • C.
Immunostaining. Thin frozen sections (5 µm) were immunolabelled and quantification of immunolabelling was performed as previously described 16 . Antibody-related information for stainings on mouse tissues and cells: PGC-1a Western blot analyses. Western blot analyses were performed as previously described 16 , using anti-PGC-1α antibody (1 µg ml −1 ; clone 4C1.3, Calbiochem ST1202) as recommended by the manufacturer. In Fig. 3b , the results were obtained with samples from the same experiment and on two separate blots that were processed in parallel.
Patient information and data collection. For the data presented in Fig. 8a , patients were diagnosed with breast cancer and tumours were surgically resected at the Department of Gynecology, University Medical Center Hamburg-Eppendorf. Written informed consent was obtained and the study was approved by the University Medical Center Hamburg-Eppendorf institutional review board. Material collection and processing were previously described 37 and RNA was characterized from patients diagnosed with IDC (all early-stage oestrogen-receptor-responsive primary tumours) with known bone marrow aspirate positivity status. Detection of disseminated tumour cells in bone marrow was performed with anti-cytokeratin monoclonal antibody A45-B/B3 as previously described 38 and according to international standards 39 . Patient information details are provided in Supplementary  Table 1 . For the data presented in Fig. 8b-d, 161 de-identified samples were collected from patients with IDC recruited for biopsy at the A. C. Carmargo Hospital, after informed consent from patients and approval by the institutional review board. The tissue microarrays were constructed from 1.50 mm cores of formalin-fixed paraffinembedded breast tissue. Immunohistochemistry was performed using the anti-PGC-1α antibody (Calbiochem ST1202, clone 4C1.3, 1 µg ml −1 ) as recommended by the manufacturer. Immunohistochemistry evaluation was performed by selecting invasive cancer cells, as defined by isolated cells, the smallest isolated nests of cells, cells from the border of solid tumours, and cells that were invading adipose tissue, stroma or micro emboli. The staining intensity for PGC-1α in these cells was automatically measured using the APERIO system. A Martingale residual plot was used for assessing a threshold for PGC-1α, and this threshold was used for correlative analyses with clinical variables (Supplementary Table 2 and Fig. 8d ) and survival (Fig. 8c) . In Fig. 8c , clinical information was missing for 3 patients to define disease-free survival. The observers were blinded when performing these analyses. For the data presented in Fig. 8e , four patients (Supplementary Table 3) were recruited for CCC enrichment at the A. C. Carmargo Hospital, after patient informed consent and approval by the institutional review board were obtained. Patient peripheral blood sample (8 ml) was collected into an EDTA tube and diluted 1:10 with ISET buffer (RareCell Diagnostics) 40 . An additional 13 IDC patients with lung metastasis were recruited for CTC evaluation as described above (Supplementary  Table 4 ). After 10 min at room temperature the sample was loaded into a well of ISET Block (RareCell Diagnostics), with 8-µm-diameter cylindrical pores, above a polycarbonate membrane. The blood sample was filtered by aspiration under vacuum of −10 kPa and then the membrane was washed by aspiration with PBS buffer. The membrane was disassembled from the ISET Block, allowed to air-dry and stored at −20 • C. The ISET membranes were then hydrated with 70 µl of Trissaline buffer (TBS) for 10 min followed by vertical draining on absorbent paper towel. In a moist chamber, the cells were permeabilized with 70 µl of TBS 0.2% Triton X-100, for 5 min at room temperature. The membranes were rinsed with TBS, incubated for 15 min in the dark at room temperature with 3% hydrogen peroxide solution, and rinsed again with TBS. The membranes were then stained using antibodies against CK8 (1:50; clone NCL-L-CK8-TS1, Novocastra), PGC-1α (1:200; clone 4C1.3, Calbiochem) or CD45 (clone 2B11 + PD7/26, Dako). For negative controls, primary antibodies were omitted. The primary antibodies were allowed to incubate for 1 h at room temperature. The membranes were then rinsed with TBS and developed using the Dual long system HRP (Dako; 30 min, room temperature) and DAB chromogen (Dako) and Permanent red (Dako; 5 min, room temperature). The membranes were then rinsed with deionized water twice and counterstained with Harris's haematoxylin for 1 min. On average 1.73 CTCs in 1 ml of blood were analysed.
Statistical analyses.
Significance was determined by one-way ANOVA or unpaired two-tailed Student's t-test and P < 0.05 was considered statistically significant. Correlative analysis for PGC-1α transcript levels in cancer cells laser-microdissected from breast tumours of IDC patients (the median dCt was used as the cut-off to define 'high' and 'low' PGC-1α transcript level) with bone marrow DTC status (positive or negative) employed a one-sided χ 2 test. Association between clinical characteristics and PGC-1α expression levels was verified by a two-tailed Fisher's exact test. For survival analysis, Kaplan-Meier curves were drawn and differences between the curves were calculated by the log-rank test 41 using R Foundation for Statistical Computing (2010) software. * P < 0.05 was considered statistically significant. Analysis of microarray data was performed using Metacore (GeneGo) and Knowledge Based Pathway (IPA; P < 0.05).
Gene expression array accession number. The gene expression array data were deposited in the Gene Expression Omnibus database (accession number GSE37344).
